GlassScriptPhysician profile
Robin Henry Dretler
NPI 1871545459
$26,740.29
in general payments reported to CMS, 2019-2025
38 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,987 · 2021: $8,306 · 2022: $1,342 · 2023: $1,485 · 2024: $2,378 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,617.77 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $18,002.81 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Gilead Sciences, INC. | $3,198.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $2,156.87 | 2019-2025 | Dificid, Pifeltro, Delstrigo |
| Abbvie INC. | $582.29 | 2019-2024 | Mavyret, Dalvance, Teflaro |
| Cumberland Pharmaceuticals, INC. | $321.71 | 2019-2023 | Vibativ |
| Janssen Scientific Affairs, LLC | $276.20 | 2019-2023 | |
| Insmed, INC. | $265.05 | 2019-2023 | Arikayce |
| Janssen Biotech, INC. | $263.83 | 2019-2023 | Symtuza |
| Astellas Pharma US INC | $193.21 | 2019-2022 | |
| Smith+Nephew, INC. | $185.51 | 2019-2024 | Collagenase Santyl, Regranex, Grafix |
| La Jolla Pharmaceutical Company | $176.69 | 2021-2023 | Xerava |
| Janssen Products, LP | $171.00 | 2019-2021 | |
| Melinta Therapeutics, LLC | $114.19 | 2019-2024 | Kimyrsa, Vabomere, Rezzayo |
| Organogenesis INC. | $98.30 | 2021-2023 | Puraply |
| Tetraphase Pharmaceuticals, INC. | $97.11 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $88.54 | 2019-2020 | |
| Kerecis Limited | $53.64 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Theratechnologies INC. | $53.28 | 2021-2023 | Trogarzo, Egrifta |
| Paratek Pharmaceuticals, INC. | $43.26 | 2020-2023 | Nuzyra |
| Ferring Pharmaceuticals INC. | $41.79 | 2022-2023 | Rebyota |
| Horizon Therapeutics Plc | $35.07 | 2021-2022 | |
| Integra Lifesciences Corporation | $32.07 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Aroa Biosurgery Incorporated | $30.97 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.46 | 2023 | Hyqvia |
| Aimmune Therapeutics, INC. | $28.01 | 2023 | |
| Mayne Pharma Commercial LLC | $24.42 | 2021 | |
| Mylan Institutional INC. | $22.48 | 2019 | |
| Next Science LLC | $20.87 | 2023 | Surgx, Blastx, Xperience |
| Nabriva Therapeutics, Plc | $20.29 | 2020 | |
| Vyera Pharmaceuticals, LLC | $17.16 | 2022 | |
| Octapharma USA, INC. | $17.15 | 2023 | Panzyga |
| Grifols USA, LLC | $16.98 | 2023 | Xembify |
| Glaxosmithkline, LLC. | $14.41 | 2022 | |
| Hydrofera LLC | $13.61 | 2022 | |
| Novo Nordisk INC | $13.20 | 2022 | |
| Reapplix INC. | $13.13 | 2022 | |
| Reprise Biomedical, INC. | $7.97 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Dretler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.